IMPORTANCE: Since the beginning of the Coronavirus Disease-19 (COVID-19) pandemic, Severe Acute Respiratory Syndrome-CoV-2 (SARS-CoV-2) infection has been a serious challenge for immune-compromised patients with immune-mediated inflammatory diseases (IMIDs). OBJECTIVE: Our aim was to investigate the impact of COVID-19 in terms of risks of infection, hospitalization and mortality in a cohort of patients with rheumatoid arthritis (RA), psoriasis (PSO) or inflammatory bowel disease (IBD). Furthermore, we studied the impact of SARS-CoV-2 infection on the prescribed drug regimen in these patients. METHODS: Through the record linkage between health information systems, a cohort of patients, ≥18 years old, assisted in the Lazio region and who had suffered from immune-mediated inflammatory diseases (RA, PSO, IBD) between 2007 and 2019, was identified. The risk of infection, hospitalization or mortality for COVID-19, was assessed by logistic regression models, and reported in an Odds Ratio (ORs; CI 95%), adjusting for sex, age and the Charlson Comorbidity Index. We also estimated these risks separately by IMID and in the subgroup of prevalent biologic drug users. We investigated deferral of biological treatments in the study population by comparing the prevalence of weekly use of biologicals (2019-2020) before and during the pandemic periods. FINDINGS: Within the 65,230 patients with IMIDs, the cumulative incidence for COVID-19 was 303/10,000 ab. In this cohort of patients, we observed a significantly higher risk of SARS-CoV-2 infection than the general population: OR = 1.17 (95% CI 1.12-1.22). The risk was higher even considering separately each disease and in the subgroup of prevalent biologic drug users. This last subgroup of patients showed a higher risk of death related to COVID-19 (OR 1.89; 95% CI 1.04-3.33) than the general population. However, no differences in terms of risks of hospitalization or death related to COVID-19 were recorded in patients with the IMIDs. Comparing the 2019-2020 prevalence of weekly biological drug treatments in prevalent biologic drug users, we found a decrease (-19.6%) during the lockdown, probably due to pandemic restrictions. CONCLUSIONS AND RELEVANCE: Patients with IMIDs seem to have a higher risk of SARS-CoV2 infection. However, other than for patients with prevalent biologic drug treatment, no significant differences in terms of hospitalization and mortality were reported compared to the general populations; further investigation is warranted on account of unmeasured confounding. In addition, during the lockdown period, the COVID-19 emergency highlighted a lower use of biologic drugs; this phenomenon requires strict pharmacological monitoring as it could be a proxy of forthcoming long-term clinical progression.
IMPORTANCE: Since the beginning of the Coronavirus Disease-19 (COVID-19) pandemic, Severe Acute Respiratory Syndrome-CoV-2 (SARS-CoV-2) infection has been a serious challenge for immune-compromised patients with immune-mediated inflammatory diseases (IMIDs). OBJECTIVE: Our aim was to investigate the impact of COVID-19 in terms of risks of infection, hospitalization and mortality in a cohort of patients with rheumatoid arthritis (RA), psoriasis (PSO) or inflammatory bowel disease (IBD). Furthermore, we studied the impact of SARS-CoV-2 infection on the prescribed drug regimen in these patients. METHODS: Through the record linkage between health information systems, a cohort of patients, ≥18 years old, assisted in the Lazio region and who had suffered from immune-mediated inflammatory diseases (RA, PSO, IBD) between 2007 and 2019, was identified. The risk of infection, hospitalization or mortality for COVID-19, was assessed by logistic regression models, and reported in an Odds Ratio (ORs; CI 95%), adjusting for sex, age and the Charlson Comorbidity Index. We also estimated these risks separately by IMID and in the subgroup of prevalent biologic drug users. We investigated deferral of biological treatments in the study population by comparing the prevalence of weekly use of biologicals (2019-2020) before and during the pandemic periods. FINDINGS: Within the 65,230 patients with IMIDs, the cumulative incidence for COVID-19 was 303/10,000 ab. In this cohort of patients, we observed a significantly higher risk of SARS-CoV-2 infection than the general population: OR = 1.17 (95% CI 1.12-1.22). The risk was higher even considering separately each disease and in the subgroup of prevalent biologic drug users. This last subgroup of patients showed a higher risk of death related to COVID-19 (OR 1.89; 95% CI 1.04-3.33) than the general population. However, no differences in terms of risks of hospitalization or death related to COVID-19 were recorded in patients with the IMIDs. Comparing the 2019-2020 prevalence of weekly biological drug treatments in prevalent biologic drug users, we found a decrease (-19.6%) during the lockdown, probably due to pandemic restrictions. CONCLUSIONS AND RELEVANCE: Patients with IMIDs seem to have a higher risk of SARS-CoV2infection. However, other than for patients with prevalent biologic drug treatment, no significant differences in terms of hospitalization and mortality were reported compared to the general populations; further investigation is warranted on account of unmeasured confounding. In addition, during the lockdown period, the COVID-19 emergency highlighted a lower use of biologic drugs; this phenomenon requires strict pharmacological monitoring as it could be a proxy of forthcoming long-term clinical progression.
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Ted R Mikuls; Sindhu R Johnson; Liana Fraenkel; Reuben J Arasaratnam; Lindsey R Baden; Bonnie L Bermas; Winn Chatham; Stanley Cohen; Karen Costenbader; Ellen M Gravallese; Andre C Kalil; Michael E Weinblatt; Kevin Winthrop; Amy S Mudano; Amy Turner; Kenneth G Saag Journal: Arthritis Rheumatol Date: 2020-12-05 Impact factor: 10.995
Authors: Robert Bm Landewé; Pedro M Machado; Féline Kroon; Hans Wj Bijlsma; Gerd R Burmester; Loreto Carmona; Bernard Combe; Massimo Galli; Laure Gossec; Annamaria Iagnocco; John D Isaacs; Xavier Mariette; Iain McInnes; Ulf Mueller-Ladner; Peter Openshaw; Josef S Smolen; Tanja A Stamm; Dieter Wiek; Hendrik Schulze-Koops Journal: Ann Rheum Dis Date: 2020-06-05 Impact factor: 27.973
Authors: Anja Strangfeld; Martin Schäfer; Philip C Robinson; Jinoos Yazdany; Pedro M Machado; Milena A Gianfrancesco; Saskia Lawson-Tovey; Jean W Liew; Lotta Ljung; Elsa F Mateus; Christophe Richez; Maria J Santos; Gabriela Schmajuk; Carlo A Scirè; Emily Sirotich; Jeffrey A Sparks; Paul Sufka; Thierry Thomas; Laura Trupin; Zachary S Wallace; Sarah Al-Adely; Javier Bachiller-Corral; Suleman Bhana; Patrice Cacoub; Loreto Carmona; Ruth Costello; Wendy Costello; Laure Gossec; Rebecca Grainger; Eric Hachulla; Rebecca Hasseli; Jonathan S Hausmann; Kimme L Hyrich; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Lianne Kearsley-Fleet Journal: Ann Rheum Dis Date: 2021-01-27 Impact factor: 19.103
Authors: Christof Specker; Anne Constanze Regierer; Rebecca Hasseli; Ulf Mueller-Ladner; Bimba F Hoyer; Andreas Krause; Hanns-Martin Lorenz; Alexander Pfeil; Jutta Richter; Martin Schäfer; Tim Schmeiser; Anja Strangfeld; Hendrik Schulze-Koops; Reinhard E Voll Journal: RMD Open Date: 2021-01
Authors: Hannah Bower; Thomas Frisell; Daniela di Giuseppe; Bénédicte Delcoigne; Gerd-Marfie Ahlenius; Eva Baecklund; Katerina Chatzidionysiou; Nils Feltelius; Helena Forsblad-d'Elia; Alf Kastbom; Lars Klareskog; Elisabet Lindqvist; Ulf Lindström; Carl Turesson; Christopher Sjowall; Johan Askling Journal: RMD Open Date: 2021-12
Authors: Dániel Honfi; Nikolett Gémes; Enikő Szabó; Patrícia Neuperger; József Á Balog; Lajos I Nagy; Gergely Toldi; László G Puskás; Gábor J Szebeni; Attila Balog Journal: Int J Mol Sci Date: 2022-09-27 Impact factor: 6.208